REDWOOD CITY, Calif.,
July 16, 2018 /PRNewswire/
-- Nevro Corp. (NYSE: NVRO), a global medical device company
that is providing innovative, evidence-based solutions for the
treatment of chronic pain, today announced preliminary unaudited
revenue for the second quarter ended June
30, 2018.
The company announced that preliminary unaudited second quarter
2018 worldwide revenue is expected to be approximately $96.1 million, compared to $78.0 million in the second quarter of 2017.
Preliminary unaudited U.S. revenue for the second quarter of
2018 is expected to be approximately $79.9
million. Preliminary unaudited international revenue for the
second quarter of 2018 is expected to be approximately $16.2 million.
The company expects worldwide revenue for the full year 2018 to
be in the range of $385.0 to
$390.0 million. This compares to
previous expectations for 2018 worldwide revenue in the range of
$400.0 to $410.0 million, as announced in May 2018.
Additionally, the Company will host a business update conference
call before market open beginning at 5:30
a.m. Pacific Time (8:30 a.m. Eastern
Time) today, Monday, July 16,
2018.
Investors interested in listening to the conference call may do
so by dialing (866) 393-4306 for U.S. callers or (734) 385-2616 for
international callers (Conference ID: 2196519), or logging into the
webcast on the "Investors" section of the Company's website
at www.nevro.com/investors. Following the call, a replay will
be available on the Investor Events and Presentations webpage of
the Company's website
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on providing innovative products that improve the quality of life
of patients suffering from debilitating chronic pain. Nevro has
developed and commercialized the Senza® spinal cord stimulation
(SCS) system, an evidence-based, non-pharmacologic neuromodulation
platform for the treatment of chronic pain. The Senza® system and
Senza II™ system are the only SCS systems that deliver Nevro's
proprietary HF10® therapy. Senza, Senza II, HF10, Nevro and the
Nevro logo are trademarks of Nevro Corp.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements with respect to our business,
capital resources, revenue projections, strategic initiatives and
growth, reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, including
continuing adoption of, and interest in, Senza in the U.S. and
international markets and our expectations for worldwide revenue
for the full year 2018. These forward-looking statements are based
upon information that is currently available to us or our current
expectations, speak only as of the date hereof, and are subject to
numerous risks and uncertainties, including our ability to
successfully commercialize our products; our ability to manufacture
our products to meet demand; the level and availability of
third-party payor reimbursement for our products; our ability to
effectively manage our anticipated growth; our ability to protect
our intellectual property rights and proprietary technologies; our
ability to operate our business without infringing the intellectual
property rights and proprietary technology of third parties;
competition in our industry; additional capital and credit
availability; our ability to attract and retain qualified
personnel; and product liability claims. These factors, together
with those that are described in greater detail in our Annual
Report on Form 10-K filed on February 22,
2018 and our Quarterly Report on Form 10-Q filed on
May 7, 2018, as well as any reports
that we may file with the SEC in the future, may cause our actual
results, performance or achievements to differ materially and
adversely from those anticipated or implied by our forward-looking
statements. We expressly disclaim any obligation, except as
required by law, or undertaking to update or revise any such
forward-looking statements. Our results for the quarter ended
June 30, 2018 are not necessarily
indicative of our operating results for any future periods.
Investor Relations Contact:
Nevro Investor
Relations
(650) 433-3247
ir@nevro.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/nevro-announces-preliminary-unaudited-second-quarter-2018-revenue-and-updates-full-year-2018-revenue-guidance-300681135.html
SOURCE Nevro Corp.